NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation- Treatment Use Study

Atrial Fibrillation Clinical Trial

— AFTX  

Official title:

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation- Treatment Use Study

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00721149
• Other study ID #: BWI03130TXA
• Status: Terminated
• Phase: Phase 3
• First received: July 21, 2008
• Last updated: December 3, 2013
• Start date: September 2008
• Est. completion date: December 2009

Study information

• Verified date: December 2013
• Source: Biosense Webster, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This trial evaluates the safety and effectiveness of catheter ablation for PAF. The investigational catheter being studied is the NAVISTAR® THERMOCOOL® irrigated-tip catheter. At the time of this study, the NAVISTAR® THERMOCOOL® Catheter was FDA-approved for commercial distribution in the U.S. for treating patients with Type I atrial flutter and drug refractory monomorphic sustained ventricular tachycardia post myocardial infarction. The catheter was approved for use in Europe for endocardial ablation for treating cardiac arrhythmias.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 10
• Est. completion date: December 2009
• Est. primary completion date: December 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with symptomatic PAF who have had three (3) AF episodes in the six (6) months prior to enrollment, one of which must be documented. Documentation may include electrocardiogram (ECG), transtelephonic monitor (TTM), Holter monitor (HM), or telemetry strip.

• Failure of at least one AAD for PAF [class I or III or AV nodal blocking agents such as beta blockers (BB) and calcium channel blockers (CCB)] as evidenced by recurrent symptomatic PAF, or intolerable side effects due to AAD.

• Signed Patient Informed Consent Form.

• Age 18 years or older.

• Able and willing to comply with all pre-, post- and follow-up testing and requirements.

Exclusion Criteria:

• Atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or reversible or non- cardiac cause.

• Previous ablation for atrial fibrillation.

• Patients on amiodarone therapy at any time during the previous six (6) months.

• AF episodes that last longer than 30 days and are terminated via cardioversion.

• Any valvular cardiac surgical procedure.

• CABG procedure within the last 180 days (six months).

• Awaiting cardiac transplantation or other cardiac surgery within the next 360 days (12 months).

• Documented left atrial thrombus on imaging (e.g. TEE).

• History of a documented thromboembolic event within the past one (1) year.

• Diagnosed atrial myxoma.

• Presence of implanted ICD.

• Significant pulmonary disease, (e.g. restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms.

• Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study.

• Women who are pregnant (by history of menstrual period or pregnancy test if the history is considered unreliable).

• Acute illness or active systemic infection or sepsis.

• Unstable angina.

• Myocardial infarction within the previous 60 days (two months).

• LVEF < 40%.

• History of blood clotting or bleeding abnormalities.

• Contraindication to anticoagulation (i.e. heparin or warfarin).

• Contraindication to CT/MRA procedure.

• Life expectancy less than 360 days (12 months).

• Enrollment in an investigational study evaluating another device or drug.

• Uncontrolled heart failure or NYHA class III or IV heart failure.

• Presence of intramural thrombus, tumor or other abnormality that precludes catheter introduction or manipulation.

• Presence of a condition that precludes vascular access.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label

Related Conditions & MeSH terms

• Arrhythmia
• Atrial Fibrillation
• Heart Diseases

Intervention

Device:
• Radiofrequency Ablation
The Biosense Webster® NAVISTAR THERMOCOOL Diagnostic/Ablation Deflectable Tip Catheter is a luminal catheter with a deflectable tip designed to facilitate electrophysiological mapping of the heart and to transmit radiofrequency current to the catheter tip electrode for ablation purposes.

Locations

Country	Name	City	State
United States	Cleveland Clinic Foundation	Cleveland	Ohio
United States	Ohio State University Medical Center	Columbus	Ohio
United States	Duke University Medical Center	Durham	North Carolina
United States	University of Rochester Medical Center	Rochester	New York

Sponsors (1)

Lead Sponsor	Collaborator
Biosense Webster, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Subjects Who Exhibited no Documented Symptomatic Paroxysmal Atrial Fibrillation (PAF) Episodes From Study Day 91 Through Day 361.	A subject who exhibited no documented symptomatic PAF episodes was one who 1) had 2 or fewer repeat ablations within 90 days of the initial ablation with investigational catheter; 2) had an addition of antiarrhythmic medication which was previously ineffective for atrial fibrillation and did not exceed the previous historical maximum dosage (24 hour total dose); 3) was on atrioventricular nodal blocking agents such as beta blockers and/or calcium channel blockers and might be maintained at the current dose (ie, did not exceed previous historical maximum dosage (24 hour total dose).	From study day 91 through day 361	No
Primary	The Percentage of Subjects Who Experienced Incidences of Early Onset (Within 7 Days of Ablation Procedure) Catheter-related Adverse Events.	Catheter-related adverse events include death, myocardial infarction, pulmonary vein stenosis, diaphragmatic paralysis, atrio-esophageal fistula, transient ischemic attack, stroke, cerebrovascular accident, thromboembolism, pericarditis, cardiac tamponade, pericardial effusion, pneumothorax, atrial perforation, vascular access complications, pulmonary edema, hospitalization (initial and prolonged), and heart block.	within 7 days of ablation procedure	Yes
Secondary	Percentage of Subjects Who Achieved Acute Success	Acute success is defined as the confirmation of entrance block in all targeted pulmonary veins. Acute failure is defined as subjects who have a non-investigational catheter used for ablation of any atrial fibrillation targets or subjects who undergo more than 2 repeat ablation procedures or an ablation procedure beyond day 90.	Day 91 - 361	Yes
Secondary	24-hour Holter Data		1 year	No
Secondary	TTM Data		1 year	No
Secondary	Percentage of Subjects Who Responded to Quality of Life Assessment	SF 36 Symptom Frequency and Severity Checklist	1 year	No